State of Wyoming’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

State of Wyoming’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-26	Closed	–	–	1237
2021 Q1	$0	Buy	+26	New	+$275	﹤0.01%	563

Other funds holding SRNE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State of Wyoming's SRNE Position: Q2 2021 in Review

State of Wyoming sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2021, closing a stake of 26 shares.

State of Wyoming first reported a position in SRNE in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 212 funds tracked by Wall St. Rank hold SRNE as of Q2 2021.

State of Wyoming reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
State of Wyoming sold 26 Sorrento Therapeutics, Inc. shares in Q2 2021.
State of Wyoming first reported a position in Sorrento Therapeutics, Inc. in Q1 2021 and held it in 1 quarter.
State of Wyoming's Sorrento Therapeutics, Inc. position peaked at $0 in Q1 2021.
212 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2021.

Based on State of Wyoming's 13F filing for Q2 2021, filed 11 Feb 2022.